Certara Scientists are Among the Topmost Cited Biopharma Researchers

Rhea-AI Summary

Certara (Nasdaq: CERT) highlighted scientific impact on Oct 20, 2025 after publishing >200 papers in the past year and placing 11 Certara scientists on the 2025 Stanford/Elsevier top 2% most‑cited researchers list.

The release notes the company’s longstanding leadership in pharmacology and pharmacokinetics, the Simcyp Simulator’s use by more than 11 global regulatory agencies and support for over 120 FDA‑approved drugs, the Simcyp Consortium’s 35 member companies, and recognition of Amin Rostami‑Hodjegan with the 2025 Lewis B. Sheiner Lecturer Award.

Positive

• 200+ papers authored by Certara scientists in the past year
• 11 Certara scientists on the 2025 top 2% most‑cited list
• Simcyp Simulator supported 120+ FDA‑approved drugs
• Simcyp used by more than 11 global regulatory agencies
• Simcyp Consortium comprises 35 biopharma member companies
• Amin Rostami‑Hodjegan received the 2025 Lewis B. Sheiner award

Negative

• None.

Certara celebrates its 200 published papers and 11 scientists on Stanford/Elsevier top 2% cited researchers list in 2025

RADNOR, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research. With more than 200 papers authored by Certara scientists* this past year and 11 Certara scientists included on the 2025 update of Stanford/Elsevier’s ranking of the top 2% most cited scientists across the globe, Certara’s powerhouse of scientific knowledge continues to drive innovation in drug discovery and development.

Certara’s highly ranked experts reflect the company’s commitment to scientific insight and developing technological solutions that further patients’ access to new medicines. Now in its 8th iteration, the list includes the most-cited researchers globally in 22 scientific disciplines and 174 sub-disciplines and encompasses standardized data on citations, h-index, and a wide range of bibliometric indicators.

“Rigorous and validated research that accelerates novel medicines drives our teams at Certara,” said William Feehery, CEO at Certara. “I’m proud of our scientists who are leading innovation in the biopharmaceutical industry.”

Certara has maintained its leadership in the multidisciplinary field of pharmacology and pharmacokinetics since the inaugural list. This year, the following Certara researchers appeared on Elsevier’s top 2% of the world’s most-cited researchers list either for the single calendar year 2024 or over the span of their entire career:

• Amin Rostami-Hodjegan, SVP of R&D and Chief Scientific Officer
• Hannah Jones, SVP, Head of Simcyp PBPK Modeling Services
• Hugo Geerts, Head of Neuroscience Modeling, QSP
• Karen Rowland Yeo, SVP, Client & Regulatory Strategy
• Khaled Abduljalil, Senior Principal Scientist
• Masoud Jamei, SVP, Simcyp R&D
• Patrick F. Smith, SVP, Translational Science
• Piet van der Graaf, SVP and Head of Quantitative Systems Pharmacology
• Rajesh Krishna, Senior Distinguished Scientist, Drug Development Solutions
• Stephen Duffull, Senior Scientific Advisor, Quantitative Science Services
• Trevor Johnson, Principal Scientist
  

Rostami-Hodjegan was also awarded the 2025 Lewis B. Sheiner Lecturer Award by the International Society of Pharmacometrics (ISoP), which recognizes the lifetime achievements of a distinguished scientist for excellence and innovation in pharmacometric research. As the co-founder of the Simcyp Simulator®, Rostami-Hodjegan’s approach to innovation and research is clear in the product’s outcomes. The Simcyp Simulator is currently used by more than 11 global regulatory agencies and has supported over 120 FDA-approved drugs in lieu of clinical studies. In addition, the Simcyp Consortium – a collaborative group of members from 35 leading biopharmaceutical companies that guides the development of the Simulator – is the longest-standing consortium of its kind and has become a global authority on mechanistic PBPK modeling and simulation.

New approach methodologies like the Simcyp Simulator are especially critical now as the biopharma industry moves to phase out animal testing, as outlined by the FDA and NIH earlier this year. PBPK modeling will continue to be at the forefront of reducing the use of animals in pre-clinical research, an effort Certara has been advancing for the last 25 years.

To learn more about how our experts are leading the pharmaceutical industry’s transition away from animal testing, please read our recent article in STAT.

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.

Certara contact:
Sheila Rocchio
Sheila.rocchio@certara.com

Media contact:
Alyssa Horowitz
certara@pancomm.com

*As found on Pubmed, affiliation is Certara; publication year is 2025

FAQ

How many Certara scientists made the 2025 Stanford/Elsevier top 2% most‑cited list for CERT?

Eleven Certara scientists were included on the 2025 Stanford/Elsevier top 2% most‑cited researchers list.

What research output did Certara report on October 20, 2025 for CERT?

Certara reported publishing more than 200 papers by its scientists in the past year.

How many FDA‑approved drugs has the Simcyp Simulator supported, according to Certara (CERT)?

The Simcyp Simulator has supported over 120 FDA‑approved drugs.

Which regulatory reach does Certara cite for the Simcyp Simulator (CERT)?

Certara states the Simcyp Simulator is used by more than 11 global regulatory agencies.

What recognition did Amin Rostami‑Hodjegan receive in 2025 mentioned by Certara (CERT)?

Amin Rostami‑Hodjegan was awarded the 2025 Lewis B. Sheiner Lecturer Award by ISoP.

How many companies are members of the Simcyp Consortium cited by Certara (CERT)?

The Simcyp Consortium includes 35 leading biopharmaceutical company members.